Novo Nordisk goes for broke on semaglutide heart data

Novo Nordisk goes for broke on semaglutide heart data

Source: 
Biopharma Dive
snippet: 

Novo Nordisk expects the Food and Drug Administration to decide by early next year on whether the drugmaker can sell its diabetes injection Ozempic and a related oral formulation as protective of heart health.